Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
| Title: | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. |
|---|---|
| Authors: | Kudo, Masatoshi, Yau, Thomas, Decaens, Thomas, Sangro, Bruno, Qin, Shukui, Da Fonseca, Leonardo, Karachiwala, Hatim, Park, Joong-Won, Gane, Edward, Pinter, Matthias, Tai, David, Santoro, Armando, Pizarro, Gonzalo, Chiu, Chang-Fang, Schenker, Michael, He, Aiwu Ruth, Hu, Nan, Jimenez Exposito, Maria Jesus, Stromko, Caitlyn, Galle, Peter Robert |
| Source: | Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p520-520, 132p |
| Database: | Supplemental Index |
Be the first to leave a comment!